Skip to content
Lower risk Drug recall · FDA · Published July 29, 2019

Upsher Smith Bexarotene Capsules Recall: Failed Dissolution Specifications

Upsher Smith recalls 75mg Bexarotene Capsules due to failed dissolution specifications. Rx-only capsules may not release medication properly. Contact for return instructions.

🇺🇸 FDA recall #D-1836-2019DrugUpsher Smith ›
Take action

Contact the company

Recalling firmUpsher Smith Laboratories, Inc.6701 Evenstad Dr N · Maple Grove, MN 55369-6026
✎ GovInfoNow plain-language explainer

Upsher Smith is recalling 75 mg Bexarotene Capsules (Rx only) because they failed dissolution specifications. This means the capsules may not release medication properly as intended, potentially affecting treatment effectiveness. Read more at govinfonow.com/recall/38200-upsher-smith-bexarotene-capsules-recall-failed-dissolution-specifications.

Source Summary by GovInfoNow · govinfonow.com/recall/38200-upsher-smith-bexarotene-capsules-recall-failed-dissolution-specifications · Updated October 5, 2026 · FDA enforcement record: FDA #D-1836-2019

Cite this page

“Upsher Smith Bexarotene Capsules Recall: Failed Dissolution Specifications.” GovInfoNow, updated October 5, 2026. https://govinfonow.com/recall/38200-upsher-smith-bexarotene-capsules-recall-failed-dissolution-specifications. Based on FDA recall #D-1836-2019 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1836-2019%22&limit=1).

Upsher Smith Laboratories, Inc. voluntarily recalled Bexarotene Capsules, 75 mg, due to failed dissolution specifications, the Food and Drug Administration said on July 29, 2019. The recall involves 166 bottles distributed in Kentucky, Ohio, New Jersey, and Louisiana.

How to tell if you have it

  • Brand: Upsher Smith
  • Product: Bexarotene Capsules, 75 mg, 100 capsules per bottle
  • NDC: 0832-0285-00
  • Lot: A2610
  • Expiration: 3/2020
  • Distribution: KY, OH, NJ, LA

The hazard

The product failed to meet dissolution specifications. The FDA classified the recall as Class II.

Context

GovInfoNow's records show Upsher Smith Laboratories, Inc. has had four other recalls since November 20, 2012. Other recent recalls of similar products include Supernus Trokendi XR 50mg Capsules (August 31, 2026), Sun Pharmaceutical Lisdexamfetamine Capsules (October 28, 2025), and AvKARE Amantadine Capsules (February 13, 2026).

How to tell if you have this one

Check for the product name 'Bexarotene Capsules', 75 mg, 100 capsules per bottle, Rx only. Look for NDC code 0832-0285-00 and lot number A2610 on the packaging.

  • Brand
    Upsher Smith
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Check Product Details

    Verify the product name, strength, and packaging details to confirm if it matches the recalled items.

  2. Contact Manufacturer

    Reach out to Upsher Smith Laboratories for specific return or disposal instructions.

Where it went and when

Where it was distributed

Distributed in 4 states.

Alaska: not listedAKMaine: not listedMEVermont: not listedVTNew Hampshire: not listedNHWashington: not listedWAIdaho: not listedIDMontana: not listedMTNorth Dakota: not listedNDMinnesota: not listedMNIllinois: not listedILWisconsin: not listedWIMichigan: not listedMINew York: not listedNYRhode Island: not listedRIMassachusetts: not listedMAOregon: not listedORNevada: not listedNVWyoming: not listedWYSouth Dakota: not listedSDIowa: not listedIAIndiana: not listedINOhio: yesOHPennsylvania: not listedPANew Jersey: yesNJConnecticut: not listedCTCalifornia: not listedCAUtah: not listedUTColorado: not listedCONebraska: not listedNEMissouri: not listedMOKentucky: yesKYWest Virginia: not listedWVVirginia: not listedVAMaryland: not listedMDDelaware: not listedDEArizona: not listedAZNew Mexico: not listedNMKansas: not listedKSArkansas: not listedARTennessee: not listedTNNorth Carolina: not listedNCSouth Carolina: not listedSCDistrict of Columbia: not listedDCOklahoma: not listedOKLouisiana: yesLAMississippi: not listedMSAlabama: not listedALGeorgia: not listedGAHawaii: not listedHITexas: not listedTXFlorida: not listedFL

FDA distribution: “KY, OH, NJ, LA” States read from FDA’s own wording; “not listed” means the notice does not name it.

States: Kentucky, Louisiana, New Jersey, Ohio.

Recall timeline

FDA terminated this recall 3.1 years after the firm started it.

1. Firm started the recall: Jul 29, 201912. FDA classified it Class II: Aug 19, 201923. Published in FDA’s Enforcement Report: Aug 28, 201934. FDA terminated the recall: Aug 25, 2022420192022
  1. Firm started the recall
  2. FDA classified it Class II
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-1836-2019 (July 29, 2019) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-1836-2019 to see it in context.
  • Plain-language summary written by qwen3:4b on October 5, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA